With short-term treatment, etanercept and adalimumab had higher efficacy results; with long-term treatment, adalimumab appeared to be the most effective. Clinicians should be aware that each of the three drugs has different rates of efficacy and different safety considerations that must be taken into account when selecting the best treatment for an individual with rheumatoid arthritis.

The quality of published reviews varies from moderate to poor. Improvements in the study design can be achieved by following specific recommendations, such as clearly describing the methods, performing the data extraction in duplicate, researching at least two databases, listing the included and excluded studies, employing tables with the main studies data and evaluating and reporting the scientific quality of the included articles.

The aim is to evaluate the humanistic outcomes in type 2 diabetic patients by the adoption of pharmacotherapy follow-up in community pharmacies. Controlled, non-randomized, 12-months trial; n=161 patients distributed into control and intervention groups; 6 community pharmacies involved, all in the Curitiba city region, in the state of Paraná were used. The health-related quality of life (HRQoL) and the satisfaction index were determined using both the DQOL assessment tool, which measures HRQoL, and the satisfaction evaluation tool (QSSF). Interventions on 119 negative therapeutic outcomes were done (2.3/patient [SD=1.6]); the most commonly found problems were related to ineffectiveness of pharmacotherapy (68.1%). The Intervention-Group showed a significant improvement in HRQoL compared with the Control Group (0.08 vs -0.01, respectively; p=0.036). Satisfaction and impact domains presented the most significant improvement (0.13 vs 0.00 [p=0.030] and 0.07 vs -0.04 [p=0.033], respectively). After adjusting for baseline variables, the difference in improvement scores between groups on the QSSF was attributed to the allocation of patients in the intervention group. Pharmacotherapy follow-up of type 2 diabetic patients in community pharmacies can improve the HRQoL and satisfaction of patients.Uniterms: Diabetes mellitus/type 2/pharmaceutical care. Pharmaceutical care. Community pharmacy. Pharmacists/community action. O objetivo foi avaliar os resultados humanísticos de pacientes com diabetes tipo 2, por meio da adoção de acompanhamento farmacoterapêutico nas farmácias comunitárias. Utilizaram-se: ensaio controlado, não-randomizado, de 12 meses; n=161 pacientes, distribuídos entre Grupo Controle e de Intervenção, e 6 farmácias comunitárias, todas na região da cidade de Curitiba, Estado do Paraná. A qualidade de vida relacionada à saúde (HRQoL) e o índice de satisfação foram determinados utilizando a ferramenta de avaliação DQOL, que mede a HRQoL, e a ferramenta de avaliação da satisfação (QSSF). Intervenções em 119 resultados terapêuticos foram efetuadas (2,3/paciente [SD=1,6]. Os problemas mais comumente encontrados foram aqueles relacionados à ineficácia da farmacoterapia (68,1%). O Grupo de Intervenção mostrou melhoria significativa da HRQoL em comparação ao Grupo Controle (0,08 versus 0,00 [p=0,030 e 0,07 versus -0,04 [p=0,033], respectivamente). Após o ajuste da linha base das variáveis, a diferença na contagem de melhoramento entre os grupos no QSSF foi atribuída à alocação de pacientes no Grupo de Intervenção. O acompanhamento farmacoterapêutico em pacientes de diabetes tipo 2 em farmácias comunitárias pode melhorar a HRQoL e a satisfação dos pacientes.Unitermos: Diabetes melito/tipo 2/atenção farmacêutica. Atenção farmacêutica. Farmácia comunitária. Farmacêuticos/ação comunitária.

The aim of this study was to evaluate the efficacy and safety of etanercept (ETA) for treating rheumatoid arthritis. A systematic review was performed to search for randomized clinical trials comparing subcutaneous doses of ETA at 25 mg twice a week or 50 mg weekly to a placebo group, with or without methotrexate. Studies of low quality (less than 3 points on Jadad’s scale) were excluded. The efficacy was assessed by using the criteria of the American College of Rheumatology (ACR). Safety data were evaluated based on serious adverse events, serious infections, malignancy and deaths. Withdrawals as a result of adverse events or lack of efficacy were also evaluated. Eight studies met the inclusion criteria, comprising 2385 patients. In the efficacy meta‐analysis, a greater number of ETA‐treated patients achieved the efficacy criteria within 6 months of treatment, where the relative risk (RR) was 2.94 [2.27, 3.81] for achieving ACR20, 5.28 [3.12, 8.92] for ACR50 and 4.83 [1.74, 13.47] for ACR70. After 1 year, the RR for achieving ACR20, ACR50 and ACR70 were 1.14 [1.07, 1.23], 1.36 [1.21, 1.53] and 1.56 [1.30, 1.88], respectively. This response rates were higher for ETA‐treated patients in comparison with control group patients. For safety, there were no statistically significant differences between treated patients and controls. This was also confirmed by withdrawals as a result of adverse events, which were not statistically different between the two groups. However, more patients withdrew from control groups because of a lack of efficacy as compared with ETA groups (RR = 0.48 [0.30, 0.78]).

No abstract